Sanofi, NIH create a three-pronged antibody to target HIV; Akari soars on PhIII plans; Juno plots planned $225M raise
⇨ A collaboration between Sanofi and the NIH led to the development of a three-pronged antibody that has shown promise in a primate model …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
